07:00 , Aug 7, 2006 |  BC Week In Review  |  Company News

Phytomedics board of directors update

Phytomedics Inc. , Jamesburg, N.J.   Business: Autoimmune, Cancer, Nutraceuticals   Appointed: Ilan Kaufthal, vice chairman of investment banking at Bear, Stearns & Co. Inc.  ...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Company News

Kos management update

Kos Pharmaceuticals Inc. (KOSP), Cranbury, N.J.   Business: Cardiovascular, Metabolic, Pulmonary   Hired: Kevin Clarke as EVP and CFO, formerly a senior managing director at Bear Stearns & Co. Inc.  ...
07:00 , Sep 29, 2003 |  BC Week In Review  |  Company News

Ariad board of directors update

Ariad Pharmaceuticals Inc. (ARIA), Cambridge, Mass.   Business: Cancer, Hematology   Appointed: Athanase Lavidas, chairman and CEO of the Lavipharm Group; and Mary Tanner, senior managing director at Bear Stearns & Co. Inc.  ...
07:00 , Apr 9, 2001 |  BC Week In Review  |  Company News

Cholestech management update

Cholestech Corp. (CTEC), Hayward, Calif.   Business: Diagnostics/Imaging   Hired: William Burke as VP of finance and CFO, formerly managing director in investment banking at Bear, Stearns & Co. Inc.; he replaces Andrea Tiller, who...
07:00 , Apr 28, 1997 |  BioCentury  |  Finance

Blech accused

A federal prosecutor has charged David Blech, a leading biotech financier in the early 1990s, with a single criminal count of securities fraud. The "criminal information," which is the equivalent of an indictment but does...
07:00 , Sep 27, 1993 |  BC Week In Review  |  Company News

Biogen news

BGEN's vice president of finance Kenneth Bates told attendees at The Bear Stearns & Co. Sixth Annual Healthcare Conference in New York that BGEN expects about a 10 percent growth in royalties in 1993. Bates...
07:00 , Sep 27, 1993 |  BC Week In Review  |  Clinical News

Genentech, Novo Nordisk regulatory update

Genentech Inc. (GNE)   Novo Nordisk (NVO)   The International Trade Commission decided to proceed with its investigation of a complaint by GNE, filed in March, alleging that Novo Nordisk 's Norditropin human growth hormone...
08:00 , Mar 1, 1993 |  BioCentury  |  Finance

Analyst picks & changes

Amgen Inc. Amgen Inc.'s announcement last week of sluggish U.S. Neupogen G-CSF sales for the quarter to date triggered a spate of analyst reappraisals on AMGN, just three weeks after lower-than-expected fourth quarter earnings sent...